Bio-Path Holdings, Inc. Announces Resignation of Douglas P. Morris as Vice President of Corporate Development and Secretary, Effective June 30, 2014
July 03, 2014 at 03:24 pm EDT
Share
On June 28, 2014, Douglas P. Morris resigned his positions as Vice President of Corporate Development and Secretary of Bio-Path Holdings, Inc., effective June 30, 2014. Mr. Morris's decision to resign was not due to any disagreement with the company's management or board of directors. Mr. Morris will continue to serve as a member of the company's board of directors.
Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the bodyâs enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Companyâs second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.
BIO-PATH HOLDINGS, INC. 
